Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2021
Date Filed: July 30, 2021
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover sheet incorporating exhibits by reference.
Exhibits Submitted:
- Exhibit 99.1: Appendix 4C and Quarterly Cash Flow Report
Material Changes
The filing text does not contain a narrative discussion of material changes versus the prior comparable period. Financial performance details are contained within the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, or specific risk factors. The registrant is identified as a development stage enterprise, implying ongoing research and development activities without commercial revenue generation at this stage.
Investor Verification Checklist
- Review Exhibit 99.1 (Appendix 4C and Quarterly Cash Flow Report) for actual financial data, as the Form 6-K text only lists the exhibit.
- Verify the company's cash burn rate and runway given its status as a development stage enterprise.
- Confirm the incorporation of this report into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-251647, 333-249311, 333-231417, 333-250076).